Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148710 | 0.85 | SIRT3 (0.43) | SMYD3RETSIRT3TDP1SOST | |
| SCHEMBL20069582 | 0.79 | SIRT3 (0.46) | SMYD3RETSIRT3TDP1SOST | |
| SCHEMBL23555223 | 0.67 | MAPT (0.32) | RETJAK2JAK1TYK2 | |
| SCHEMBL21159143 | 0.66 | RET (0.31) | RET | |
| SCHEMBL20160370 | 0.65 | RET (0.32) | RET | |
| SCHEMBL20148706 | 0.65 | PIK3CD (0.54) | TDP1PIK3CD | |
| SCHEMBL20148712 | 0.64 | P2RX7 (0.40) | RETTDP1 | |
| SCHEMBL23555022 | 0.63 | PIK3CD (0.52) | TDP1PIK3CD | |
| SCHEMBL3100795 | 0.61 | TDP1 (0.68) | SMYD3SIRT3TDP1TYK2 | |
| SCHEMBL29496054 | 0.61 | TDP1 (0.68) | SMYD3SIRT3TDP1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | SMYD3 1818/4885RET 1/4885SIRT3 4404/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | SMYD3 1818/4885RET 1/4885SIRT3 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.